CellaVision ABCVLLY +12.06%69 3-Year ROIIC % is 24.77 as of Dec. 2025, which is 174% above its 10-year median of 9.05. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 801 Medical Devices & Instruments companies, CellaVision AB ranks better than 74.03% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
CellaVision AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 24.77%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for CellaVision AB's 3-Year ROIIC % or its related term are showing as below:
CVLLY's 3-Year ROIIC % is ranked better than 74.03% of 801
companies
in the Medical Devices & Instruments industry
Industry Median: 1.06
vs CVLLY: 24.77
CellaVision AB (OTCPK:CVLLY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
CellaVision AB 3-Year ROIIC % Related Terms
CellaVision AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's 3-Year ROIIC % falls into.
CellaVision AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 17.133484 (Dec. 2025) - 12.1573 (Dec. 2022) )
/
( 93.535 (Dec. 2025) - 70.897 (Dec. 2022) )
=
4.976184
/
22.638
=
21.98%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
CellaVision AB (CVLLY) has a 3-Year ROIIC % of 24.77 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CellaVision AB and its competitors. This is 174% above median its historical median of 9.05. According to the industry distribution chart, CellaVision AB ranks #208 out of 801 companies in the Medical Devices & Instruments industry, placing it in the top 26%.
Is CellaVision AB's 3-Year ROIIC % too high?
CellaVision AB's current 3-Year ROIIC % of 24.77 is 174% above median its 10-year median of 9.05. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.06. CellaVision AB's value of 24.77 is 2236.8% above this industry median. Based on the distribution chart, CellaVision AB ranks #208 out of 801 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #208 out of 801 companies for 3-Year ROIIC %. This puts CellaVision AB in the upper half of its industry. The industry median 3-Year ROIIC % is 1.06. CellaVision AB's value of 24.77 is 2236.8% above this benchmark. While the company's 10-year median is 9.05 vs. the industry median of 1.06, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.06, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current 3-Year ROIIC % of 24.77 is 2236.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current 3-Year ROIIC % is 24.77, which is 174% above median its own 10-year median of 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current 3-Year ROIIC % is 24.77, which is 174% above median its 10-year median of 9.05 and 2236.8% above the Medical Devices & Instruments industry median of 1.06. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current 3-Year ROIIC % is 24.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
3-Year ROIIC %: 24.77 (174% above median its 10-year median of 9.05)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 2236.8% above the Medical Devices & Instruments median (#208 of 801)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
